臨床試驗

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT：NCT06329570 · SUSPENDED

NCT IDNCT06329570

狀態SUSPENDED

開始日期2024-10-22

完成時間2028-03-31

SponsorNaviFUS Corporation (INDUSTRY)

First posted2024-03-26

Last updated2026-09-09

簡要摘要

This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。